The increase and spread of bacterial resistance to extended-spectrum beta-lactam antibiotics are reported in many infections and are a real public health problem worldwide. Drug pressure is a factor that favors the em...The increase and spread of bacterial resistance to extended-spectrum beta-lactam antibiotics are reported in many infections and are a real public health problem worldwide. Drug pressure is a factor that favors the emergence of a population of better adapted bacteria. However, there is no literature highlighting the genetic diversity and evolutionary structure of E. coli and K. pneumoniae in an environment with high selection pressure in Côte d’Ivoire. The objective of this study was to evaluate the genetic diversity of E. coli and K. pneumoniae strains circulating at the HKB Hospital in Abobo and at the Daloa Regional Hospital and its impact on the dissemination of extended spectrum beta-lactam resistance genes. A total of 39 strains isolated from the urinary tract of infected patients, including 30 strains of E. coli and 9 strains of K. pneumoniae were studied. A total of 39 strains isolated from the urinary tract of infected patients, including 30 strains of E. coli and 9 strains of K. pneumoniae were studied. From genomic DNA extracts, ESBL resistance genes were amplified by PCR and sequenced, in addition to genetic typing by ERIC-PCR. The data obtained were submitted to genetic and bioinformatics analyses. The results have shown a genetic diversity important in E. coli and K. pneumoniae with diversity indexs (SID) ranging from 0.5 to 0.77. The genetic structure of the bacterial species studied has shown a clonal distribution of strains with clones expressing TEM-9 and CTX-M-15 variants. Also, this clonal structure was correlated with the spread of resistance genes in E. coli and K. pneumoniae. The spread of resistant clones is a factor that might limit the fight against antibiotic resistance.展开更多
包括青霉素在内的β-内酰胺类药物用于治疗A族链球菌(group A Streptococcus,GAS)感染已有80余年,虽然体外试验尚未发现对其耐药的GAS菌株,但自20世纪50年代以来,时有β-内酰胺类药物临床治疗GAS感染失败的报道。GAS体内耐受β-内酰胺...包括青霉素在内的β-内酰胺类药物用于治疗A族链球菌(group A Streptococcus,GAS)感染已有80余年,虽然体外试验尚未发现对其耐药的GAS菌株,但自20世纪50年代以来,时有β-内酰胺类药物临床治疗GAS感染失败的报道。GAS体内耐受β-内酰胺类药物的机制尚未明确。已有研究提示,GAS体内耐受β-内酰胺类药物与菌株对药物的敏感性降低、细菌的接种效应、生物膜的形成、共存菌的作用、细菌持留性及细菌可内化入胞内等因素有关。该文回顾总结了β-内酰胺类药物临床治疗GAS感染失败的主要报道,以及与GAS体内耐受β-内酰胺类药物机制相关的重要研究,为后续研究及临床用药提供参考。展开更多
文摘The increase and spread of bacterial resistance to extended-spectrum beta-lactam antibiotics are reported in many infections and are a real public health problem worldwide. Drug pressure is a factor that favors the emergence of a population of better adapted bacteria. However, there is no literature highlighting the genetic diversity and evolutionary structure of E. coli and K. pneumoniae in an environment with high selection pressure in Côte d’Ivoire. The objective of this study was to evaluate the genetic diversity of E. coli and K. pneumoniae strains circulating at the HKB Hospital in Abobo and at the Daloa Regional Hospital and its impact on the dissemination of extended spectrum beta-lactam resistance genes. A total of 39 strains isolated from the urinary tract of infected patients, including 30 strains of E. coli and 9 strains of K. pneumoniae were studied. A total of 39 strains isolated from the urinary tract of infected patients, including 30 strains of E. coli and 9 strains of K. pneumoniae were studied. From genomic DNA extracts, ESBL resistance genes were amplified by PCR and sequenced, in addition to genetic typing by ERIC-PCR. The data obtained were submitted to genetic and bioinformatics analyses. The results have shown a genetic diversity important in E. coli and K. pneumoniae with diversity indexs (SID) ranging from 0.5 to 0.77. The genetic structure of the bacterial species studied has shown a clonal distribution of strains with clones expressing TEM-9 and CTX-M-15 variants. Also, this clonal structure was correlated with the spread of resistance genes in E. coli and K. pneumoniae. The spread of resistant clones is a factor that might limit the fight against antibiotic resistance.
文摘包括青霉素在内的β-内酰胺类药物用于治疗A族链球菌(group A Streptococcus,GAS)感染已有80余年,虽然体外试验尚未发现对其耐药的GAS菌株,但自20世纪50年代以来,时有β-内酰胺类药物临床治疗GAS感染失败的报道。GAS体内耐受β-内酰胺类药物的机制尚未明确。已有研究提示,GAS体内耐受β-内酰胺类药物与菌株对药物的敏感性降低、细菌的接种效应、生物膜的形成、共存菌的作用、细菌持留性及细菌可内化入胞内等因素有关。该文回顾总结了β-内酰胺类药物临床治疗GAS感染失败的主要报道,以及与GAS体内耐受β-内酰胺类药物机制相关的重要研究,为后续研究及临床用药提供参考。
